Analyzing Immunic (NASDAQ:IMUX) & Psyence Biomedical (NASDAQ:PBM)

Immunic (NASDAQ:IMUX) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Profitability

This table compares Immunic and Psyence Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
Psyence Biomedical	N/A	N/A	N/A

Insider & Institutional Ownership

51.8% of Immunic shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Immunic and Psyence Biomedical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61 million	($1.23)	-0.82
Psyence Biomedical	N/A	N/A	-$51.16 million	N/A	N/A

Risk & Volatility

Immunic has a beta of 1.73, suggesting that its stock price is 73% more volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of -0.11, suggesting that its stock price is 111% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Immunic and Psyence Biomedical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0	0	6	2	3.25
Psyence Biomedical	0	0	0	0	0.00

Immunic presently has a consensus target price of $13.20, suggesting a potential upside of 1,206.93%. Given Immunic’s stronger consensus rating and higher probable upside, equities analysts clearly believe Immunic is more favorable than Psyence Biomedical.

About Immunic

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.